Enseignants

Yogeshvar Kalia,

Objectif

non renseigné

Description

Cette journée est organisée par les doctorants eux-mêmes.
Les intervenants de cette journée sont les doctorants qui sont dans le 5e/6e semestre de leur thèse.
Le but du PhD Day est:
- accroître les échanges scientifiques entre doctorants et professeurs/chercheurs travaillant dans différents domaines au sein des Sciences Pharmaceutiques aussi bien que dans des domaines apparentés,
- stimuler l’interdisciplinarité dans la recherche, point fondamental pour les Sciences Pharmaceutiques.

Cette activité engageant toutes les disciplines des sciences pharmaceutiques.

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Yogeshvar Kalia, Alexis Poulet,

Objectif

non renseigné

Description

Course given by Alexis Poulet, Vice President R&D Executive Office, Head of Global Portfolio & Project Management, Ferring Pharmaceuticals

Divided in two sessions, this course will help you to “manage the project right” and “manage the right projects” in the pharmaceutical industry.

Project Management in Pharma:
Driving a pharmaceutical product to the market safely and quickly is a long, complex and demanding process. Yet, it is critical for pharmaceutical companies to manage research and development projects well, to bring their products to patients. The objective of the course is to examine how to structure projects with a strategic approach, thorough planning, identification of milestones, stakeholder management and development of precise objectives, to bring drugs to the market. The complex drug-development process from lab to launch includes management of several business processes, such as technical development using quality by design, regulatory strategy, clinical studies, and supply chain. These processes are affected not only by many circumstantial factors, but also interdependencies. The identification of risks at the right stage and an effective mitigation plans are key for success. If the risks are not managed in a timely and effective manner, the complexity of the situation increases and chances of success reduce dramatically.

Portfolio Management in Pharma:
Portfolio management has been widely adopted by the pharmaceutical and biotech industry because of the unique characteristics of drug development: huge investments, long development timelines, extremely high risk, and need for diversification in the pipeline. Portfolio management is about selecting, out of all projects, which should be funded, how they should be funded, and which should be stopped.

In this course in two sessions you will:
· Get an overview of pharmaceutical project management through the concepts of Quality, Time, Cost versus Risk.
· Understand the different types of pharmaceutical development projects with concrete examples
· Get familiar with specific terms used during the pharmaceutical development
· Understand why companies need portfolio management and how to they define their approach
· Put the theory into practice with group exercises

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Nicolas Widmer, Nicolas Widmer,

Objectif

L'adaptation posologique sur la base d'une mesure de concentration sanguine de médicament s’inscrit dans le cadre global du « Suivi thérapeutique des médicaments » (TDM). Diverses situations cliniques peuvent motiver une telle démarche, mais tous les médicaments ne possèdent, toutefois, pas l’ensemble des caractéristiques requises pour un programme de TDM. Alors que fléchit le nombre de nouveaux médicaments commercialisés, le pilotage fin des traitements existants est appelé à connaître d’importants progrès.
L’objectif du cours est d’apprendre une pratique rationnelle du TDM, depuis la discussion de l’indication à une mesure de concentration jusqu’à l’adaptation posologique, en utilisant, pour cette dernière, autant des règles simples que des approches sophistiquées par calcul bayésien.

Description

Grâce à un mélange d'explications théoriques (jour 1 surtout) et d'exercices pratiques (jour 2 surtout), le cours abordera les thématiques principales suivantes:
- Rappel de pharmacocinétique
- Introduction à l'individualisation posologique et au TDM
- Stratégies d'adaptation posologique à la lumière de cas cliniques
- Niveau de preuve du TDM et études coût-bénéfice

Bibliographie

N. Widmer, et al. Suivi thérapeutique des médicaments (I). Les principes. Revue Médicale Suisse 2008; 4(165): 1644-1648.
N. Widmer, et al. Suivi thérapeutique des médicaments (II). La pratique clinique. Revue Médicale Suisse 2008; 4(165): 1649-1660.
T. Buclin, et al. Monitoring drug therapy. British Journal of Clinical Pharmacology 2012; 73(6): 917-923
LA. Decosterd, et al. The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine. Trends in Analytical Chemistry 2016; 84, Part B: 5-13.
T. Buclin, et al. The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib. Frontiers in Pharmacology 2020; 11:177.

Mode d'examen

Aucun / Attestation

Enseignants

Yogeshvar Kalia, Alex Satz,

Objectif

non renseigné

Description

Course given by Dr Alex SATZ

The course will first describe how different screening technologies are used in the pharmaceutical industry to discover hit molecules, including the pros and cons of each approach.
Then we will discuss how DNA-encoded library (DEL) screening is used, and some case-studies will be shown.
Lastly, we will discuss in-depth how DELs are produced, selected against, and the data interpreted.

About the lecturer:
Alex Satz has 15+ years experience building and leading DNA encoded library (DEL) technology platforms, and is currently the senior director of DEL strategy and operations at WuXi AppTec. DEL provides the means to discover novel chemical matter that modulates key biological targets, a common first step in discovering new medicines. Prior to joining WuXi AppTec, Alex built and led the Roche DEL platform in Basel Switzerland and Nutley USA, and helped to develop the first industrial-scale DEL platform at Praecis Pharmaceuticals (located near Boston USA, and later purchased by GlaxoSmithKline). Alex also worked as a medicinal chemist at AstraZeneca, was an NIH postdoctoral fellow at Harvard Medical School, and earned his PhD in organic chemistry from the University of California Santa Barbara. In the field of DEL, Alex has authored 16 peer-reviewed articles and two book chapters.

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Yogeshvar Kalia, Leonardo Lauciello,

Objectif

non renseigné

Description

Course given by Dr Leonardo Lauciello, Global Portfolio and Program Manager at Roche pRED


Summary:

This module is dedicated to understanding how a company creates and manages its portfolio of R&D projects, and how business development from the buy side can help complement the gaps in the portfolio.

Module description:

In the part dedicated to portfolio management, we will talk about strategy, project positioning, decision making, and project evaluation tools like Probability of Technical Success (PTS) and valuations.

From the business development perspective, we will have a look at the basics of scouting, deal making and analyze some example deals.

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Daniele Roppolo, Daniele Roppolo,

Objectif

non renseigné

Description

• Principles of Scientific Integrity as formulated in the The European Code of Conduct for Research Integrity, 2023 (All European Academies) and the violation of scientific integrity as formulated in the Code of conduct for scientific integrity, 2021, by the Swiss academies of arts and science
• UNIGE policy on ethical conduct of science as formulated in the Code of ethics and professional conduct for the Geneva institutions of higher education
• Integrity in data management, use of resources, publications and authorships, CVs, applications, patenting, relationships with colleagues and collaborators
• Protection of whistleblowers at UNIGE, procedures to follow in case of witnessing misconduct, UNIGE integrity line, UNIGE help line.

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Leonardo Scapozza, Bodo Baumeister,

Objectif

Course given by Dr Bodo BAUMEISTER

Course Outline:
The objective of this course is to gain an overview of the pharmaceutical & biotech industry, its history, structure and challenges and the organisational structure of pharmaceutical companies. Starting with an overview of the industry, the course will explore some of the most pressing challenges the industry faces. During the final session 2 executives from the industry will discuss the opportunities and challenges they are facing with the participants.

Description

Schedule:
- Day 1: Industry Overview: History, Industry Structure, Challenges and Organisational Structures
- Days 2-4: Challenges Facing the Industry: Case Studies
- Day 5: Meet the Industry

Preparation Needed:
- Day 1: None
- Days 2-4: Prepare Case Studies: 20 hours
- Day 5: Prepare Interview with Industry Executives: 1 hour

Please note: The date of Day 5 may change depending on the availability of the industry executives participating; any change in the date will be discussed with the participants to ensure that everyone can attend.

Time:
On each day the course will take place between 10am-1pm and 2-5pm.

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Yogeshvar Kalia, Pierre Humbert-Droz,

Objectif

Course given by Dr Géraldine Bouvier, Director Global Regulatory Affairs, GSK Consumer Healthcare (Ex Novartis Consumer Health SA Nyon) and Dr Pierre Humbert-Droz, Regulatory Affairs, CMC Expert Consultant (MITC SA) / GSK Consumer Healthcare


The objective of this course is to give an overview of the worldwide regulatory environment and regulatory requirements governing the pharmaceutical industry.
It will provide an understanding of this dynamic discipline which combines science & regulations and offers large opportunities for interesting careers at the interface between pharmaceutical company’s various departments.
It will describe the regulatory environment in the major regions of the globe to support development of new products to obtain marketing authorizations.
This course will also provide an introduction to the lifecycle management, focusing on drug products & medical devices together with considerations on trends and future within the pharmaceutical industry.

Description

non renseigné

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Leonardo Scapozza, Raluca Flückiger, Kamran Houshangpour, Daniel Kraus,

Objectif

non renseigné

Description

Ce cours couvrira les éléments suivants :
- Notions de base de propriété intellectuelle
- Les différentes procédures de dépôt de brevet
- Stratégie en matière de brevets
- Les brevets en tant que source d'information
- « Publish or perish « ou « publish and perish »
- Droites et obligations découlant des brevets
- Transfert de technologie : cession ou licence de brevet ?

Les brevets dans leur contexte : Droits, obligations, exceptions ; les procédures de dépôt de brevet ; le rôle des brevets dans les activités de transfert de technologie : Comment aligner la stratégie de commercialisation et celle de protection de la propriété intellectuelle? Qu'est-ce qui vaut la peine d'être protégé? Comment maximiser les chances de valoriser ses découvertes? Le brevet en tant que source d'information ; le brevet, ses alternatives, ses compléments : droit d'auteur, secret d'affaire et certificat complémentaire de protection ; la titularité des droits de propriété intellectuelle, leur exploitation commerciale.
Exercice pratique : Chaque participant amène un cas concret de recherche.

Bibliographie

Bibliographie: Wagret, J-M. : Brevets d'invention, marques et propriété industrielle, édition Presses universitaires de France, collection Que sais-je ? No 1143, 7ème édition, décembre 2001., « Inventing the Future » : an introduction to patents for Small and Medium Enterprises, Intellectual Property for Businesse No 3, Publicaiton de l'OMPI, Genève 2005, accessible sur internet a l'adresse: http://www.wipo.int/freepublications/en/sme/917/wipo pub 917.pdf, Feldmann, CP.: International Invention Guide, IFIA Publication No.2, 1994, ISBN 2-940103-01-1

Mode d'examen

non renseigné

Enseignants

Antoine Daina, Antoine Daina, Vincent Zoete,

Objectif

Employing computing resources algorithms and 3D visualization to rationally design novel molecules that activate or inhibit the function of a therapeutically relevant protein became a key element of any industrial or academic drug discovery projects. Computer-assisted drug design (CADD) aims at generating rational ideas about how to create or modify the molecules and at helping to promote the most promising drug candidates at each stage of the process, from early hit finding to late preclinical development1.
The objective of this one-day workshop is two-fold:
i) Providing the necessary theoretical background and an overview of existing software and databases in order to ii) let the participant himself discover, design, optimize and evaluate novel active virtual molecules by two different approaches (based on freely available web-based tools developed by the Molecular Modeling Group at the Swiss Institute of Bioinformatics).
The final goal is for non-expert participants (being pharmacist, biologist, chemists, physicist or MD) to acquire the right technical skills to achieve basic drug design tasks on whatever computer connected to the Internet with enough theoretical background to interpret the outputs and make them relevant outcomes in any project involving biological activity of small molecules.

Description

The lecture part covers:
• The basics of drug discovery project
• An overview of CADD approaches and technics5
• A description of methods to predict ADME, druglikeness and toxicity of molecules.
• The theoretical background explaining the recognition of drug molecules by protein targets and the estimation of affinity.
• Detailed presentation of molecular docking methods and binding free energy estimation2.
• Detailed presentation of bioisosteric design approaches.

The practical part consists in the use of freely available web-based tools to design, optimize and evaluate molecules, making use of the 3D structure of the protein target (structure-based drug design) or less (ligand-based drug design):
• SwissDock3,6: molecular docking to evaluate and visualize how a drug molecule bind to a protein target.
• SwissBioisostere4,7: bioisosteric replacement methodology to design of new molecular scaffolds or optimize existing ones.
• SwissADMEbeta: prediction of druglikeness, ADME and toxicity of molecules.

Bibliographie

1. Seddon, G. et al. Drug design for ever, from hype to hope. J Comput Aided Mol Des 26, 137–150 (2012).
2. Zoete, V., Cuendet, M. A., Grosdidier, A. & Michielin, O. SwissParam: a fast force field generation tool for small organic molecules. J. Comput. Chem. 32, 2359–2368 (2011).
3. Grosdidier, A., Zoete, V. & Michielin, O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 39, W270–7 (2011).
4. Wirth, M., Zoete, V., Michielin, O. & Sauer, W. H. B. SwissBioisostere: a database of molecular replacements for ligand design. Nucleic Acids Res. 41, D1137–43 (2013).
5. http://www.click2drug.org
6. http://www.swissdock.ch
7. http://www.swissbioisostere.ch

Mode d'examen

Attestation based on the evaluation of the practical work.

Enseignants

Yogeshvar Kalia, Francois-Xavier Abellan, Julien Boccadoro, Ann Stroemberg,

Objectif

Course given by: Dr François-Xavier Abellan, Ferring Saint-Prex Mr Julien Boccadoro, Ferring Saint-Prex Ms Ann Stroemberg, Ferring Copenhagen

Pharmaceuticals are considered as the most highly regulated industries worldwide.
Quality, from research and development stages through production, testing and post-marketing surveillance by applying the principles of Quality by Design (QbD), Quality Assurance (QA), and the Good Practices (GxPs), is essential to ensure the safety, quality and efficacy of medicines.
The Quality in Pharmaceuticals course is designed for people who have no knowledge of the GxP in the pharmaceutical industry.
The Objective with this course is to understand the importance of Quality in the development and manufacturing of products in the pharmaceutical industry:
• You get to know the most important pharmaceutical regulations and their application areas
• You get a basic overview and understanding of the quality requirements applied in the pharmaceutical industry
• You get an overview of Pharmaceutical Development and Quality by Design principles
• You become familiar with specific terms in the field of GxP and their meaning

Description

non renseigné

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Yogeshvar Kalia, Alexis Poulet,

Objectif

The class will provide a comprehensive overview of the pharmaceutical industry, focusing on the key drivers of value creation. We will explore the global industry landscape, highlighting the differences between innovation-driven products and the role of generics.
The course will cover the research and development (R&D) process, its critical stages, and the financial investments required.
Additionally, we will discuss the high level complexities of market access, including the role of payers, pricing strategies, and regulatory influences that impact drug availability and reimbursement. By the end of the session, participants will gain a solid understanding of the industry's core components and evolving trends

Description

non renseigné

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Yogeshvar Kalia, Toufik Abbas-Terki, Daniel Kraus, Goranka Tanackovic,

Objectif

non renseigné

Description

Course given by Dr Goranka TANACKOVIC, CEO, Gene Predictis; Dr Toufik Abbas-Terki, Consultant chez Abbas-Terki; Prof Daniel Kraus, UniNE


Course Outline:

• Overview of the personalized/precision medicine today (prognostic aspects, diagnostic aspects and therapeutic aspects with challenges and achievements in all three of them, new tendencies) (3h)

• Development of precision medicine product (starting form a case study and analyzing different aspects of product development: idea, proof of concept, clinical validation, regulatory requirements, reimbursement, how to bring such a product to the market) (3h)

• Regulatory and legal aspects (2h)

• Case studies preparation (2h, homework)

• Intellectual property related to life sciences, the Swiss situation (2h)

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Yogeshvar Kalia, Xavier Chauchet, Walter Ferlin, Nicolas Fischer, Franck Gueneau, Christophe Guillamo, Eric Hatterer, Flora Juan, Adeline Lesnier, Giovanni Magistrelli, Sara Majocchi, Stéphane Moutel, Yves Poitevin, Ulla Ravn, Jenna Salti,

Objectif

non renseigné

Description

• Overview of the steps for drug development (90', NF, WF)
• Therapeutic antibody formats and discovery platforms (45', SM)
• Toolbox to streamline the identification of Antibody Drug Candidate (45', GM)
• Antibody discovery using display technologies (45', UR, FG)
• Preclinical drug development: in vitro and in vivo pharmacology (45', EH)
• Introduction to bioanalysis and clinical sample testing (45', AL)
• Manufacturing of bispecific antibodies (45', YP, CG)
• Development of a bispecific antibody for cancer therapy (45', XC)
• Supporting Biotechs: the role of QA (30', JS)
• Supporting Biotechs: the role of Project Management (30', SM, FJ)

• Visit of LCB facilities (60')

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Yogeshvar Kalia,

Objectif

Le séminaire annuel extra muros a pour but de permettre aux doctorants et aux post-doctorants d’approfondir leurs connaissances dans une des disciplines principales en sciences pharmaceutiques.

Description

non renseigné

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Patrycja Nowak-Sliwinska, Intidhar Labidi-Galy, Patrycja Nowak-Sliwinska,

Objectif

Clinical oncologists from HUG will give an overview of current treatments and challenges for different types of cancer. The objective is to give PhD students insights into the clinical aspects of cancer treatment, to better understand the unmet needs, as well as the realities of clinical research in this field.

Description

Teacher responsible : Patrycja Nowak-Sliwinska and Carole Bourquin

The lecture is given by Dr. Intidhar Labidi-Galy, HUG, Faculty of Medicine and other clinical oncologists

Typical questions to be discussed:

-What are the treatment options for a particular type of cancer?

-How do you decide on the treatment for each patient?

-What are the current clinical challenges? What do you need from basic research?

Format:

lecture followed by a round table discussion

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Patrycja Nowak-Sliwinska, Patrycja Nowak-Sliwinska,

Objectif

The objectives of this course are to get PhD students in pharmaceutical/biomedical research programs familiar with the following subjects:

- Modern approaches in combination treatment design
- Common pharmacokinetic mechanisms underlying clinically important interactions between drugs
- Interactions between drugs used in cancer therapy and nutrients
- Patient- and drug-related factors that predispose patients to adverse drug interactions. There will be case-based discussions on approaches to clinical evaluation and management of the risk of drug-drug interactions.
- Novel targets for anti-cancer drugs, including vasculature
- Combination therapy in onco-immunology.
- Personalized and precision medicine
Learning Objectives: The learning objectives for this course are to:
- acquire a scientific understanding of the physiological and biochemical basis of drug-drug interactions,
- be able to apply the knowledge gained to the prevention and intervention of adverse drug interactions, as the recognition of the potential for, and intervening with, the adverse consequences of drug-drug and food-drug interactions are major responsibilities of practicing pharmacists.
- develop basic skills of modern combination therapies.

By the end of the course, the students should be able to use the tools and knowledge introduced in the course for new scientific questions related to drug actions.

Description

The course will consist of expert lectures, case-based discussions, e-learning

Bibliographie

There is no textbook. The materials will be delivered via e-mail.

Mode d'examen

Course grade will be calculated based on scores for the exam (60%), case studies (20%) and ratings for active participation in the course (20%).

Enseignants

Emerson Ferreira Queiroz, Emerson Ferreira Queiroz,

Objectif

Ce cours a pour but d'approfondir les connaissances des doctorants en chromatographie à l’échelle préparative pour la purification des composés d’origine organique (produits naturels ou composés obtenus par synthèse).

Description

Dans le cas de produits naturels, l'isolement de substances pures à partir des extraits des plantes et microorganismes est souvent une procédure longue et difficile qui nécessite l'accès à une large gamme de techniques chromatographiques de séparation. Ces mêmes techniques sont souvent aussi utilisées pour la séparation de composés obtenus par synthèse organique.
Ce cours montrera les différentes étapes nécessaires à l’obtention d’un composé pur, en commençant par la préparation de l’échantillon et le choix d’une technique de chromatographie.
Différentes techniques chromatographiques seront présentées pour la séparation des composés ayant une large gamme de polarité.
Des séances de travaux pratiques sont aussi prévues pour que les étudiants puissent appliquer les connaissances acquises à des problèmes réels de séparation.


Contenu: Extraction, préparation d'échantillon, chromatographie sur colonne, chromatographie flash (FC), chromatographie à moyenne pression (MPLC), chromatographie à haute pression (Semi-prep. HPLC), chromatographie de partage centrifuge, stratégies de séparation.

Bibliographie

K. Hostettmann, A. Marston, M. Hostettmann (1998) Preparative Chromatography Techniques – Applications in Natural Product Isolation, 2nd ed., Springer-Verlag, Berlin.

Queiroz EF, Wolfender JL (2014). Innovative Strategies in the Search for Bioactive Plant Constituents, in ‘Handbook of Chemical and Biological Plant Analytical Methods’, edited by Kurt Hostettmann, Shilin Chen, Andrew Marston and Hermann Stuppner. Chichester, UK: John Wiley & Sons, Ltd, pp 967-986.

Challal S, Queiroz EF, Debrus B, Kloeti W, Guillarme D, Wolfender JL. (2015) Rational and efficient preparative isolation of natural products by MPLC-UV-ELSD based on HPLC to MPLC gradient transfer. Planta Medica, 81, 1636-1643

Mode d'examen

attestation

Enseignants

Farshid Sadeghipour, Renaud Pichon, Farshid Sadeghipour,

Objectif

Dans le cadre de la Maîtrise universitaire d’études avancées (MAS) en Pharmacie Hospitalière, des séminaires sont organisés à l’intention des candidats au MAS et sont ouverts également à un plus large public professionnel.

Description

Différents thèmes de management seront abordés, entre autres en lien avec l’exercice de la profession de pharmacien.

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Farshid Sadeghipour,

Objectif

non renseigné

Description

Ce séminaire consacré aux dispositifs médicaux (DM) et matériovigilance (MV) est à nouveau organisé à l'intention des candidats à la maîtrise universitaire d'études avancées (MAS) en pharmacie hospitalière. Cet enseignement est également ouvert à tous les pharmaciens ainsi qu'au autres universitaires et professionnels de la santé désireux d'approfondir leurs connaissances dans le domaine des DM et MV.

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Johnny Beney,

Objectif

Dans le cadre de la Maîtrise universitaire d’études avancées (MAS) en Pharmacie Hospitalière, des séminaires sont organisés à l’intention des candidats au MAS et sont ouverts également à un plus large public professionnel. Ils auront lieu à l’Institut Central à Sion

Description

Après avoir suivi le séminaire, les participants:
• comprennent les principes de management de la qualité
• Connaissent les bases de la technique d’audit et peuvent collaborer avec les organismes de certification dans le cadre des audits RQPH
• Connaissent les développements actuels au niveau de la qualité et de la sécurité et peuvent intégrer leur démarche pharmaceutique dans le contexte global
• Comprennent les principes de gestion du risque et d’incident

Bibliographie

non renseigné

Mode d'examen

attestation

Enseignants

Pascal Bonnabry,

Objectif

Dans le cadre de la Maîtrise universitaire d’études avancées (MAS) en Pharmacie Hospitalière, des séminaires sont organisés à l’intention des candidats au MAS et sont ouverts également à un plus large public professionnel.

Description

non renseigné

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Farshid Sadeghipour,

Objectif

non renseigné

Description

non renseigné

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Farshid Sadeghipour, Farshid Sadeghipour,

Objectif

Ce séminaire consacré à la préparation des médicaments parentéraux à l’hôpital est à nouveau organisé à l’intention des candidats à la maîtrise universitaire d'études avancées (MAS) en pharmacie hospitalière. Cet enseignement est également ouvert à tous les pharmaciens ainsi qu’aux autres universitaires et professionnels de la santé désireux d'approfondir leurs connaissances dans le domaine de la préparation des médicaments parentéraux.

Description

non renseigné

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Yogeshvar Kalia, Frederic Zenhausern,

Objectif

The goal of this “Space Pharm” module of the graduate program at UNIGE is to educate about the vast opportunities available within the space ecosystem, and to prepare the students to innovate into biomedical and pharmaceutical sciences using space and planetary-based technologies to benefit people on Earth and for future human exploration and resilience.

Description

non renseigné

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Yogeshvar Kalia,

Objectif

To get a basic knowledge and awareness of ethics in research by completing 4 online modules: module 1, 2, 3 and 4 on https://elearning.trree.org/

Description

Course topic:
To provide the students with the bases of ethics related to research or clinical trial management.
Learned skills and content

Module 1: Module 1 is an introductory module that presents the basics of research ethics evaluation and the broader context of research ethics. It is designed for anyone intimately or remotely involved with research involving humans.

You must get the correct answer before moving ahead. At the end of this module, a certificate is available for participants who got 70% correct answers on their first try.

Module 2: Module 2 focuses on the training needs of members of Research Ethics Committees (RECs) and any support function. It is also relevant to other stakeholders in the field such as researchers and their teams, or students of faculties who train researchers, who develop research projects and/or who conduct research. Module 2 addresses elements that should be considered when assessing if research is ethically acceptable.

You must get the correct answer to each question before moving ahead. At the end of this module, a certificate is available for participants who got 70% correct answers on their first try.

Module 3: Informed consent is a key requirement for participation in research. It was covered briefly in Section 3.7 of Module 2; the present Module discusses the concept and its application in greater detail.

You must get the correct answer before moving ahead. At the end of this module, a certificate is available for participants who got 70% correct answers on their first try.

Module 4: This module is a current and comprehensive guide to the elements and principles of Good Clinical Practice (GCP) quality standards for clinical trials. This module is complementary to Modules 1, 2 and 3 of the TRREE Training program. Those modules need to be completed prior to beginning this one.



Fee for the Delivery of the 4. Good Clinical Practice (GCP) module TRREE Certificate
TRREE’s philosophy is based on the right to education and provides free on-line access to e-learning modules. However, the maintenance of the programme and the steady control of its quality, in particular through a regular update of its content, are not without a cost. In order to sustain and bolster the programme, we are therefore introducing a 50 Swiss Francs fee for the delivery of the official Certificate for the 4 Good Clinical Practice (GCP) module. This amount will be collected only from participants from high income economies (as identified in the 2016 World Bank’s list). We thank you for your understanding and your support that will allow us to continue providing a high quality, accurate and up-to-date training programme in research ethics and regulation worldwide. Access to the training module itself remains free. Only the delivery of the GCP module Certificate will be charged.

Agenda (may be subject to modifications):
12h – 20 h (e-learning sessions, homework, readings…) + lectures 5.5h.

Bibliographie

non renseigné

Mode d'examen

validation en ligne des modules de e-learning

Enseignants

Yogeshvar Kalia, Yogeshvar Kalia, Béatrice Kaufmann, Florence von Ow,

Objectif

non renseigné

Description

Réunion de tous les doctorants faisant une thèse portant la mention sciences pharmaceutiques.

Des informations détaillées sur le programme doctoral en sciences pharmaceutiques seront données, ainsi que sur les filières de doctorat mention sciences pharmaceutiques: Doctorat ès sciences, mention sciences pharmaceutiques et Doctorat ès sciences de la vie, mention sciences pharmaceutiques.

Des informations essentielles seront présentées, et les doctorants auront la possibilité de poser des questions à la Direction du programme.

Présence obligatoire pour tout nouveau doctorant.

Meeting for all PhD students pursuing a PhD Thesis mention Pharmaceutical sciences.

Detailed information will be presented, as well as specific information concerning the two types of PhDs: PhD in sciences, mention pharmaceutical sciences, and PHD in Life sciences, mention pharmaceutical sciences.

The PhD Program in pharmaceutical sciences will be presented, and the PhD students will have the opportunity to discuss with the program's Direction.

The presence of every newcoming PhD Student is mandatory

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Gérard Hopfgartner, G Hopfgartner, Sophie Michalet,

Objectif

The major objectives of the course is to be up to date with the most commonly used mass spectrometric techniques hyphenated with separation sciences for the qualitative and quantitative analysis of elements, low-molecular weight compounds and macromolecules (peptides and proteins).

Description

Contents:

Historical aspects of mass spectrometry

Ionization techniques

Mass analyzers

GC HPLC, SFC, CE hyphenated to mass spectrometry

Ion mobility mass spectrometry

Data Acquisition and Processing

MS in Drug Metabolism

Bibliographie

See Moodle

Mode d'examen

Examen oral.

Enseignants

Oscar Vadas, Alexandre Hainard, Oscar Vadas,

Objectif

October 31: 13h00 - 14h00
November 7, 8, 14, 15, 21: 13h00 - 17h00

Participation is limited to 8 people
Register following the instructions enclosed in the message received from Dylan Walser (around 1 month before course starts)

Description

Session comprises both :
1) Theoretical presentations by students and tutors
2) Hands-on experimental part
Methodologies:
Cell lysis, centrifugation / Protein purification by affinity chromatography / Enzymatic activity test and SDS-PAGE analysis
In-gel protein digestion for Mass Spectrometry data generation and analysis
Theoretical part:
Protein engineering and purification strategies
Principles of a mass spectrometer analyzer and mass spectrometry applications

Evaluation: Student individual presentations and redaction of a scientific report

Bibliographie

non renseigné

Mode d'examen

non renseigné

Enseignants

Serge Rudaz, Julien Boccard,

Objectif

Ce cours a pour but d'initier les étudiants à la pratique des plan d'expériences pour la recherche expérimentale en sciences pharmaceutiques. Cette approche permet une planification optimale des essais dans la perspective d'obtenir un maximum d'information sur le phénomène observé.

Description

Ce cours alterne en salle informatique des aspects théoriques et pratique et permet à l'étudiant d'aborder les aspects de traitement de résultats. Après un bref rappel sur les notions de régression multilinéaire, d'analyse de variance et de calcul matriciel, cette formation aborde différents plans d'expériences utiles en sciences pharmaceutiques: criblage, plan factoriel complet, plan du second degré, plan de mélange.
A l'aide d'un support logiciel, la construction, l'usage et le choix de ces plans est présenté. Pour chaque plan, un exemple est présenté et traité par l'étudiant.

Bibliographie

Introduction aux plans d'expériences
Jacques Goupy , Lee Creighton Dunod , L'Usine Nouvelle

Mode d'examen

Contrôle individuel des compétences (basé sur travail personnel et présentation orale)